Home  >  News
Corporate + Font Resize -

Biocon’s Vishakhapatnam API facility completes US FDA inspection

Our Bureau, Bengaluru
Wednesday, September 20, 2017, 12:10 Hrs  [IST]

Biocon has announced that it successfully cleared the US Food and Drug Administration (FDA) audit for its active pharmaceutical ingredients (API) manufacturing facility in Vishakhapatnam, Andhra Pradesh. The audit was from September 11 to 15, 2017.
 
The facility has completed the audit without any observations. No form 483 was issued. The successful audit of this facility reflects our strong commitment to cGMP compliance at our manufacturing facilities, stated the company spokesperson.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
anbu rahul Oct 19, 2017 4:50 PM
useful to me
 
CPhI-WW-Banners-150X60-120618-anim-v2
pharmalytica_150x60_2018
CPhI_MEA_Banner_150x60_2018
150X60px_biowavers
IPE_2018_Banner_150X60
GPRS_150x60_2018
cphikorea_150x60_saffron media
Chemspec_India-2018
CPhI_China_150x60-2018
PharmaTech_Expo_2018
VF118_Banner_150x60_E_D2
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |